LoadingLoadingLoadingNet selling: insiders sold $4.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $16K to $65K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Sells/Trims (3)
Citadel
$169.4M
sold
Millennium
$139.3M
trimmed
AQR
$69.2M
trimmed
No tracked top-trader positions in GMED as of Oct 24, 03:27 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
$1.10 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$1.13 to $1.26
Revenue expected
14 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $1.34 / $1.10Yahoo Finance | +21.91% beat | $789.6M No estimate | Unavailable |
| Mar 31, 2026 | May 7, 2026 | $1.12 / $0.92Yahoo Finance | +21.73% beat | $759.9M No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $1.28 / $1.15Yahoo Finance | +10.96% beat | $826.4M No estimate | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | $1.18 / $0.78Yahoo Finance | +51.14% beat | $769.0M No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $0.86 / $0.76Alpha Vantage | +13.16% beat | $745.3M No estimate | Unavailable |
| Mar 31, 2025 | May 8, 2025 | $0.68 / $0.75Alpha Vantage | -9.33% miss | $598.1M No estimate | Unavailable |
| Dec 31, 2024 | Feb 20, 2025 | $0.84 / $0.75Alpha Vantage | +12.21% beat | $657.3M No estimate | Unavailable |
| Sep 30, 2024 | Nov 5, 2024 | $0.83 / $0.65Alpha Vantage | +27.69% beat | $625.7M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $769.0M | $826.4M | $759.9M | $789.6M |
| Cost of what it sold | $282.4M | $231.3M | $234.1M | $241.4M |
| Gross profit | $486.7M | $595.1M | $525.8M | $548.2M |
| What it spent | ||||
| Research and development | $38.1M | $73.9M | $36.5M | $36.3M |
| Sales and admin | $313.6M | $318.5M | $297.8M | $286.8M |
| Other operating costs | — | $31.1M | $29.5M | $42.6M |
| Total operating expenses | $351.7M | $423.4M | $363.8M | $365.7M |
| What was left | ||||
| Operating profit | $135.0M | $171.7M | $163.6M | $182.4M |
| Interest on debt | $1.5M | — | $5.4M | — |
| Profit before tax | $144.0M | $174.1M | $157.1M | $189.8M |
| Tax | $25.0M | $33.4M | $32.8M | $38.2M |
| Net profit | $119.0M | $140.6M | $124.3M | $151.6M |
| EBITDA | $215.1M | $244.4M | $226.9M | $259.3M |
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is neutral
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
NeutralOct 1231 macro signals shaping GMED right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
